Rheumatoid arthritis and renal light-Chain deposition disease: Long-Term effectiveness of TNF-a blockade with etanercept

Research output: Contribution to journalArticle

Abstract

A 68-year-old woman diagnosed with erosive rheumatoid arthritis (RA) was treated with intramuscular methotrexate 15 mg weekly and oral prednisone 5 mg daily. A favorable outcome of 6 years was followed by RA flare and nephrotic syndrome (NS). Renal biopsy revealed non-amyloid light-chain deposition disease. Laboratory analysis and bone marrow biopsy excluded monoclonal protein and plasma cell dyscrasia. Addition of subcutaneous etanercept, 25 mg twice weekly allowed rapid control of both arthritis and NS. To date, after over 7-year follow-up, RA is in clinical remission, 24-h albuminuria is consistently below 0.5 g, and serum creatinine is 0.9 mg/dl.

Original languageEnglish
Pages (from-to)909-912
Number of pages4
JournalInternational Urology and Nephrology
Volume43
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Rheumatoid Arthritis
Nephrotic Syndrome
Kidney
Light
Biopsy
Paraproteinemias
Albuminuria
Prednisone
Methotrexate
Arthritis
Creatinine
Bone Marrow
Serum
Etanercept
Proteins

Keywords

  • Etanercept
  • Renal Light-Chain Deposition disease
  • Rheumatoid arthritis
  • TNF-blockade
  • Tumor Necrosis Factor-alpha (TNF-alpha)

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

@article{504a39bf508e438ea8c4b461cc38addf,
title = "Rheumatoid arthritis and renal light-Chain deposition disease: Long-Term effectiveness of TNF-a blockade with etanercept",
abstract = "A 68-year-old woman diagnosed with erosive rheumatoid arthritis (RA) was treated with intramuscular methotrexate 15 mg weekly and oral prednisone 5 mg daily. A favorable outcome of 6 years was followed by RA flare and nephrotic syndrome (NS). Renal biopsy revealed non-amyloid light-chain deposition disease. Laboratory analysis and bone marrow biopsy excluded monoclonal protein and plasma cell dyscrasia. Addition of subcutaneous etanercept, 25 mg twice weekly allowed rapid control of both arthritis and NS. To date, after over 7-year follow-up, RA is in clinical remission, 24-h albuminuria is consistently below 0.5 g, and serum creatinine is 0.9 mg/dl.",
keywords = "Etanercept, Renal Light-Chain Deposition disease, Rheumatoid arthritis, TNF-blockade, Tumor Necrosis Factor-alpha (TNF-alpha)",
author = "Lorenzo Cavagna and Vincenzo Sepe and Francesca Bobbio-Pallavicini and Filippo Mangione and Roberto Caporali and Carlomaurizio Montecucco",
year = "2011",
month = "9",
doi = "10.1007/s11255-010-9788-6",
language = "English",
volume = "43",
pages = "909--912",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Rheumatoid arthritis and renal light-Chain deposition disease

T2 - Long-Term effectiveness of TNF-a blockade with etanercept

AU - Cavagna, Lorenzo

AU - Sepe, Vincenzo

AU - Bobbio-Pallavicini, Francesca

AU - Mangione, Filippo

AU - Caporali, Roberto

AU - Montecucco, Carlomaurizio

PY - 2011/9

Y1 - 2011/9

N2 - A 68-year-old woman diagnosed with erosive rheumatoid arthritis (RA) was treated with intramuscular methotrexate 15 mg weekly and oral prednisone 5 mg daily. A favorable outcome of 6 years was followed by RA flare and nephrotic syndrome (NS). Renal biopsy revealed non-amyloid light-chain deposition disease. Laboratory analysis and bone marrow biopsy excluded monoclonal protein and plasma cell dyscrasia. Addition of subcutaneous etanercept, 25 mg twice weekly allowed rapid control of both arthritis and NS. To date, after over 7-year follow-up, RA is in clinical remission, 24-h albuminuria is consistently below 0.5 g, and serum creatinine is 0.9 mg/dl.

AB - A 68-year-old woman diagnosed with erosive rheumatoid arthritis (RA) was treated with intramuscular methotrexate 15 mg weekly and oral prednisone 5 mg daily. A favorable outcome of 6 years was followed by RA flare and nephrotic syndrome (NS). Renal biopsy revealed non-amyloid light-chain deposition disease. Laboratory analysis and bone marrow biopsy excluded monoclonal protein and plasma cell dyscrasia. Addition of subcutaneous etanercept, 25 mg twice weekly allowed rapid control of both arthritis and NS. To date, after over 7-year follow-up, RA is in clinical remission, 24-h albuminuria is consistently below 0.5 g, and serum creatinine is 0.9 mg/dl.

KW - Etanercept

KW - Renal Light-Chain Deposition disease

KW - Rheumatoid arthritis

KW - TNF-blockade

KW - Tumor Necrosis Factor-alpha (TNF-alpha)

UR - http://www.scopus.com/inward/record.url?scp=80555133253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80555133253&partnerID=8YFLogxK

U2 - 10.1007/s11255-010-9788-6

DO - 10.1007/s11255-010-9788-6

M3 - Article

C2 - 20559723

AN - SCOPUS:80555133253

VL - 43

SP - 909

EP - 912

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 3

ER -